RAB10: an Alzheimer's disease resilience locus and potential drug target
Clinical interventions in aging, 2019•Taylor & Francis
Alzheimer's disease (AD) is mainly a late-onset neurodegenerative disorder. Substantial
efforts have been made to solve the complex genetic architecture of AD as a means to
identify therapeutic targets. Unfortunately, to date, no disease-altering therapeutics have
been developed. As therapeutics are likely to be most effective in the early stages of disease
(ie, before the onset of symptoms), a recent focus of AD research has been the identification
of protective factors that prevent disease. One example is the discovery of a rare variant in …
efforts have been made to solve the complex genetic architecture of AD as a means to
identify therapeutic targets. Unfortunately, to date, no disease-altering therapeutics have
been developed. As therapeutics are likely to be most effective in the early stages of disease
(ie, before the onset of symptoms), a recent focus of AD research has been the identification
of protective factors that prevent disease. One example is the discovery of a rare variant in …
Alzheimer’s disease (AD) is mainly a late-onset neurodegenerative disorder. Substantial efforts have been made to solve the complex genetic architecture of AD as a means to identify therapeutic targets. Unfortunately, to date, no disease-altering therapeutics have been developed. As therapeutics are likely to be most effective in the early stages of disease (ie, before the onset of symptoms), a recent focus of AD research has been the identification of protective factors that prevent disease. One example is the discovery of a rare variant in the 3′-UTR of RAB10 that is protective for AD. Here, we review the possible genetic, molecular, and functional role of RAB10 in AD and potential therapeutic approaches to target RAB10.
Taylor & Francis Online以上显示的是最相近的搜索结果。 查看全部搜索结果